This study is designed as a randomized control trial which intends to determine if transperineal (TP) targeted biopsy is not inferior to transrectal (TR) targeted biopsy for diagnosis of clinically significant prostate cancer while comparing post-procedural infection rates between the two techniques. The study will also look to compare patient reported pain scores related to the procedure, rates of other minor complications (e.g. bleeding, urinary retention) and procedure time. The expected sample size at The Ottawa Hospital is 360 men.
1 Primary · 1 Secondary · Reporting Duration: Patients who have undergone biopsy of the prostate will be seen by their Urologist in routine clinical follow-up, typically in 4-6 weeks, as per standard of care.
Active Control
Experimental Treatment
360 Total Participants · 2 Treatment Groups
Primary Treatment: Transperineal (TP) Ultrasound (US) Targeted Fusion Biopsy · No Placebo Group · N/A
Age Any Age · Male Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: